THE ADVI ANGLE

Resources and insights to help you keep up with policy and market trends in a transforming healthcare ecosystem

Showing Articles

BCBS ‘Evidence Street’ Group Enabling Engagement
With MDx Players

ADVI Chief Clinical Officer Louis Jacques MD was recently interviewed by GenomeWeb, a highly regarded outlet for news in the molecular diagnostic test arena, about the planned collaboration of BCBSA Evidence Street and the Palmetto GBA Medicare MolDX program. Jacques noted that Medicare has used external technology assessments to inform some of its national coverage policy decisions, so the paradigm is not inconsistent with CMS precedents. He reassured readers that MolDX would be expected use the publicly transparent current Local Coverage Determination process, and that Evidence Street would not be writing Medicare coverage policies.

Read more

Marc Samuels Featured in FierceHealthcare

Written by Leslie Small
Tuesday, 24 January 2017

Though the executive branch has limited power to dismantle the ACA, the order was “more than symbolic,” said Marc Samuels, CEO of the consulting firm ADVI and a former healthcare policy adviser under President George H.W. Bush.

Read more

Trump’s healthcare nominees are just what the doctor ordered

Written by Lindsay Bealor Greenleaf
Contribution by Marc Samuels
Sunday, 1 January 2017

In a January column of The Hill, ADVI Founder and CEO Marc Samuels and ADVI Director Lindsay Bealor Greenleaf share their take on President Elect Donald Trump’s nominees for two of the highest health care positions under the incoming administration. While much of the media is focused on how these two nominees may affect ACA repeal and replace efforts, there are even greater implications for the Medicare program as implementation of MACRA unfolds in 2017.

Read more

Roche spends $1 billion on Foundation Medicine’s tumor profiling

With companion diagnostics’ growing importance in the development of precision medicines, pharma’s interest in gaining stakes in diagnostics companies makes sense. “Pharma companies are deep-pocketed partners with a great deal of FDA experience, and the agency eventually wants to regulate LDTs,” says Marc Samuels, president and CEO of ADVI, a Washington, DC–based healthcare advisory services firm. “Greater ownership of a diagnostics firm allows a pharma to better manage and control the fate of its pipeline in an era where biomarkers are the key to faster approvals with smaller clinical trials.”

Read more